SPRI Clinical Trials Now Enrolling Patients for Study of New Treatment for Depression
Posted on: Monday, 15 October 2007, 15:00 CDT
NEW YORK, Oct. 15 /PRNewswire/ -- SPRI Clinical Trials announced today that it is now screening patients for enrollment in the parAGOn Clinical Trial Program, which will start with two Phase III studies to evaluate the efficacy, safety and tolerability of agomelatine, a novel, investigational, once-daily medication for the treatment of Major Depressive Disorder (MDD). The 8-week, randomized, placebo-controlled studies are sponsored by Novartis Pharmaceuticals Corporation, and each of the two Phase III studies will include 490 patients from approximately 50 centers.
This investigational new drug targets both melatonin receptors and serotonin (5-HT2c) receptors.
The parAGOn Clinical Trial Program is open to patients between the ages of 18 and 70 who are experiencing MDD and meet other eligibility criteria. Eligible patients will be equally randomized to receive either treatment with agomelatine 25 mg, agomelatine 50 mg or placebo once daily for 8 weeks. Patients who complete the eight-week double-blind treatment phase may also participate in a 52-week open-label extension of the study.
MDD is the most common mood disorder, affecting approximately 15 million American adults, according to the National Alliance on Mental Illness. Common symptoms include: depressed mood, loss of interest in daily activities, poor concentration, weight loss (or gain), decrease of appetite, sleep disturbance, feelings of worthlessness and /or of guilt, and suicidal ideation. Episodes of depression may be chronic and recurrent, according to the National Institute of Mental Health.
Contact Dr. Nick Vatakis at 888-345-7774 for more information about the ParAGOn Clinical Trial Program.
SPRI Clinical Trials
CONTACT: Nick Vatakis, M.D., Medical Director of SPRI Clinical Trials+1-888-345-7774
Web site: http://www.spristudy.com/
Source: PRNewswire
Related Articles
- BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- BTG Completes Treatments in Phase II Safety Study of Varisolve
- Artes Medical Announces Enrollment of First Patient in 1000 Patient Post-Marketing ArteFill Study for Treatment of Smile Line Wrinkles
- Results of Ceftobiprole Phase III Program for the Treatment of Complicated Skin Infections Presented Today at ICAAC
- Medivir: Lipsovir(R) - All Patients in the Phase III Program Now Enrolled
- Secondary Endpoints of Phase II/III Study Confirm Clear Benefits From Treatment With Removab(R) for Patients With Malignant Ascites
- CollaGenex Pharmaceuticals Announces Positive Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Acne
- Seattle Genetics Initiates Phase II Clinical Trial of SGN-40 for the Treatment of Non-Hodgkin's Lymphoma
- Evotec Initiates Phase II Clinical Trial With EVT 201 for the Treatment of Insomnia
 |
 |
User Comments (0)
RSS Feeds